Heart & Lung Health has recently teamed up with Caristo Diagnostics, a renowned cardiac disease diagnostics company, to introduce the innovative CaRi-Heart® AI technology across the UK. This partnership aims to provide early diagnosis of coronary artery disease, a condition that affects many adults in the UK who experience chest pain.
The CaRi-Heart technology, pioneered by Caristo Diagnostics, utilizes artificial intelligence to predict the risk of developing potentially fatal coronary artery disease by assessing coronary inflammation and integrating plaque and clinical risk factors such as cholesterol levels. This groundbreaking technology is able to detect coronary inflammation in routine CCTAs, providing a non-invasive Fat Attenuation Index Score™ as a biomarker for identifying at-risk patients.
Research studies have shown that patients with abnormal CaRi-Heart test results, even if they initially displayed no plaque or calcium during a CCTA, have significantly higher risks of cardiac mortality and major adverse cardiac events compared to those with normal test results. By incorporating the CaRi-Heart AI-based cardiac assessment as part of Heart & Lung Health’s cardiac health check package, patients across multiple sites in the UK will have access to this advanced diagnostic tool.
Heart & Lung Health, a network of expert cardiothoracic radiologists, is committed to delivering rapid and precise imaging reports that prioritize patient care. The organization’s partnership with Caristo Diagnostics represents a significant step towards enhancing the accessibility of CaRi-Heart technology and potentially saving thousands of lives by enabling early detection of coronary artery disease.
The collaboration between Caristo Diagnostics and Heart & Lung Health underscores the importance of early diagnosis and intervention in improving health outcomes for patients at risk of coronary artery disease. By deploying the CaRi-Heart technology UK-wide, both organizations are dedicated to revolutionizing risk prediction and management of this life-threatening condition.
With a focus on providing world-class patient care and leveraging cutting-edge technology, Heart & Lung Health and Caristo Diagnostics are poised to make a meaningful impact on the diagnosis and treatment of coronary artery disease in the UK.Through their joint efforts, they aim to transform the landscape of cardiac diagnostics and empower healthcare providers to deliver personalized care to those at risk of heart-related complications.
